PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.10
Ask: 3.40
Change: -0.10 (-2.99%)
Spread: 0.30 (9.677%)
Open: 3.35
High: 3.35
Low: 3.25
Prev. Close: 3.35
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer

Wed, 13th Dec 2023 09:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Impellam Group PLC, up 26% at 819.12 pence, 12-month range 580.00p-950.00p. Shares in the staffing firm rise, though back off from new 52-week high, after it says it has agreed to a GBP483.2 million takeover offer from Heather Global PLC, a bidding vehicle for HeadFirst Global BV. The HeadFirst offer values each Impellam share at 1,084.4 pence in total. This represents a 67% premium over the stock's 650.00p close in London on Tuesday. The offer is supported by Impellam's majority owner Michael Ashcroft, a UK businessman who was formerly deputy chair of the UK Conservative Party.

----------

Allergy Therapeutics PLC, up 9.5% at 2.13p, 12-month range 0.37p-5.64p. The biotechnology firm, focused on allergy vaccines, updates on G306 Phase III trial of Grass MATA MPL, its short-course subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. It notes "highly significant secondary efficacy endpoints with an acceptable safety and tolerability profile observed for Grass MATA MPL." Chief Executive Manuel Llobet says: "We are very pleased that the primary and secondary endpoints from this trial strongly align, and all data analysed demonstrate the beneficial effect of our Grass MATA MPL product. These data, alongside the results from our earlier G309 field study, provide a strong, significant and consistent data package for our discussions with relevant health authorities."

----------

AIM - LOSERS

----------

Future Metals NL, down 12% at 1.30p, 12-month range 1.13p-6.40p. The West Perth-based exploration company focused on the Panton platinum group metals project in Western Australia says its shares have been suspended on the Australian Securities Exchange in Sydney pending the release of an announcement in relation to a "potential capital raising". The company's shares continue to trade as normal on AIM in London.

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
22 Sep 2022 15:48

UK earnings, trading statements calendar - next 7 days

Friday 23 September 
Biffa PLCTrading Statement
European Opportunities Trust PLCFull Year Results
Investec PLCTrading Statement
Smiths Group PLCFull Year Results
TheWorks.co.uk PLCFull Year Results
Monday 26 September 
Atome Energy PLCHalf Year Results
Chapel Down Group PLCHalf Year Results
Concurrent Technologies PLCHalf Year Results
CPPGroup PLCHalf Year Results
Devolver Digital IncHalf Year Results
Dillistone Group PLCHalf Year Results
Finsbury Food Group PLCFull Year Results
Frenkel Topping Group PLCHalf Year Results
Immotion Group PLCHalf Year Results
Likewise Group PLCHalf Year Results
Microlise Group PLCHalf Year Results
Next Fifteen Communications PLCHalf Year Results
SpaceandPeople PLCHalf Year Results
XLMedia PLCHalf Year Results
Xpediator PLCHalf Year Results
Tuesday 27 September 
AG Barr PLCHalf Year Results
Animalcare Group PLCHalf Year Results
Billington Holdings PLCHalf Year Results
Boku IncHalf Year Results
Card Factory PLCHalf Year Results
Close Brothers Group PLCFull Year Results
Diaceutics PLCHalf Year Results
Digitalbox PLCHalf Year Results
ECSC Group PLCHalf Year Results
Ergomed PLCHalf Year Results
Ferguson PLCFull Year Results
FireAngel Safety Technology Group PLCHalf Year Results
GENinCode PLCHalf Year Results
Gresham House Energy Storage Fund PLCHalf Year Results
K3 Capital Group PLCFull Year Results
Instem PLCHalf Year Results
LifeSafe Holdings PLCHalf Year Results
Medica Group PLCHalf Year Results
Mission Group PLCHalf Year Results
Mortgage Advice Bureau PLCHalf Year Results
NAHL Group  PLCHalf Year Results
Origin Enterprises PLCFull Year Results
United Utilities Group PLCTrading Statement
Personal Group Holdings PLCHalf Year Results
S&U PLCHalf Year Results
Saga PLCHalf Year Results
Serica Energy PLCHalf Year Results
SSP Group PLCTrading Statement
tinyBuild IncHalf Year Results
Transense Technologies PLCFull Year Results
Yu Group PLCHalf Year Results
Wednesday 28 September 
1Spatial PLCHalf Year Results
AVI Japan Opportunity Trust PLCHalf Year Results
Avingtrans PLCFull Year Results
Blancco Technology Group PLCFull Year Results
boohoo Group PLCHalf Year Results
Everyman Media Group PLCHalf Year Results
Octopus Renewables Infrastructure Trust PLCHalf Year Results
Shepherd Neame LtdFull Year Results
Skillcast Group PLCHalf Year Results
SolGold PLCFull Year Results
Thursday 29 September 
Allergy Therapeutics PLCFull Year Results
Angle PLCHalf Year Results
Avation PLCFull Year Results
Bango PLCHalf Year Results
Cap-XX LtdHalf Year Results
Celadon Pharmaceuticals PLCHalf Year Results
Crestchic PLCHalf Year Results
Directa Plus PLCTrading Statement
McBride PLCFull Year Results
NAHL Group PLCHalf Year Results
Next PLCHalf Year Results
Novacyt SAHalf Year Results
Physiomics PLCFull Year Results
Synairgen PLCHalf Year Results
XLMedia PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
15 Jul 2022 11:58

Allegy Therapeutics trades 'robustly' in tough year

(Sharecast News) - Allergy Therapeutics updated the market on the financial year just ended on Friday, with the phase one 'Peanut PROTECT' trial, incorporating "ground-breaking" VLP technology, proceeding as planned, with site initiation visits imminent.

Read more
15 Jul 2022 10:33

Allergy Therapeutics expects lower revenue, warns on higher costs

(Alliance News) - Allergy Therapeutics PLC on Friday said it expects annual revenue to fall and, while sales are set to improve in the year ahead, it flagged higher costs.

Read more
26 May 2022 22:00

TRADING UPDATES: DP Eurasia posts strong sales growth on Turkey demand

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
4 Mar 2022 20:53

TRADING UPDATES: IOG to cut Gazprom ties; wholesale changes at Donegal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News:

Read more
3 Mar 2022 19:32

TRADING UPDATES: Avation loss narrows; Franchise Brands profit rises

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
2 Feb 2022 13:25

TRADING UPDATES: Longboat comes up empty; Intercede wins US contract

TRADING UPDATES: Longboat comes up empty; Intercede wins US contract

Read more
26 Jan 2022 12:17

Allergy Therapeutics gets US FDA approval for peanut vaccine trial

Allergy Therapeutics gets US FDA approval for peanut vaccine trial

Read more
13 Jan 2022 20:20

TRADING UPDATES: Mobile Streams wins deal; East Imperial revenue jumps

TRADING UPDATES: Mobile Streams wins deal; East Imperial revenue jumps

Read more
15 Nov 2021 16:05

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
27 Oct 2021 14:37

EXECUTIVE CHANGES: GSK adds scientific heft to board ahead of demerger

EXECUTIVE CHANGES: GSK adds scientific heft to board ahead of demerger

Read more
25 Oct 2021 10:45

Allergy Therapeutics reports positive results from field study

(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive top-line results from its exploratory field study 'G309' to evaluate the efficacy and safety of its short-course subcutaneous allergen-specific immunotherapy candidate 'Grass MATA MPL'.

Read more
25 Oct 2021 09:18

Allergy Therapeutics shares jump on positive G309 trial results

Allergy Therapeutics shares jump on positive G309 trial results

Read more
23 Sep 2021 11:48

EARNINGS UPDATES: Harbour Energy enters black; Fonix profit rises

EARNINGS UPDATES: Harbour Energy enters black; Fonix profit rises

Read more
13 Sep 2021 20:25

IN BRIEF: Allergy Therapeutics cheers secondary endpoint results

IN BRIEF: Allergy Therapeutics cheers secondary endpoint results

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.